An International, Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Efficacy and Tolerability of ZOMIG 2.5 mg (Orally Dispersible Tablet) in theAcute Treatment of Adult Patients with Migraine (311CIL/0107). NOTE: The orally dispersible tablet will be discussed hereafter as the orally disintegrating tablet.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].